Godavari Drugs Standalone March 2022 Net Sales at Rs 44.28 crore, up 34.35% Y-o-Y

Godavari Drugs standalone net profit declines 1.55% in the March 2022 quarter

Godavari Drugs standalone net profit rises 67.06% in the June 2021 quarter

Godavari Drugs Standalone March 2021 Net Sales At Rs 32.96 Crore, Up 34.87% Y-o-Y

Godavari Drugs standalone net profit rises 69.74% in the March 2021 quarter

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Godavari Drugs is engaged in the contract manufacturing, loan license manufacturing, manufacturing and supply of active pharmaceutical ingredients (APIs), drug intermediaries and fine chemicals